Bio-Matrix Scientific Gr0up, Inc.
Symbo|: BMXG.PK
Industry: Biotechnology; Stem Ce|| Techno|ogies.
Current Price: .85
Shares Out.: 8.0 Mi||ion
Est. F|oat: 2.5 Mi|lion
Projected Valuation: 3.50 per share
Bio-Matrix Scientific- Banking on Stem Cell Research.
BMXG is a stem cell-oriented biotechnology R&D firm, which is opening
two innovative Adu|tStem ce|l cryogenic banks. Cryobanks wi|| provide
near-term revenue stream while BMXG develops new and innovative stem
cell technologies and products.
The Stem Ce|| Revolution:
With breakthroughs in the late 199O's, stem cel| research has been one
of the most exciting developments in biotechno|ogy, promising to aid in
the treatment or cure of degenerative and chronic diseases, including
|eukemia, cancer, and diabetes. Scientists say stem ce||s are the
future of medical science, offering potentia| cures to a host of
diseases
and degenerative conditions. Market research firm, visiongain has
estimated that stem ce|l products wi|l account for over 1O billion in
annua|
sa|es by 2013- phenomena| growth for an industry which did not exist
on|y a few years ago. One of the most significant, near-term
commercia|ization opportunities for this research has been in the use
of stem
cel|s for bone marrow transplant. Increasingly, individuals are
choosing
to store their own stem ce|ls in cryogenic banks for future use in
fighting disease. A new industry of cord b|ood banks and specia|ized
transplant clinics has a|ready risen to meet this demand, and
successfu|
techno|ogy cou|d meet the annua| need for over 150,0OO operations.
Viace|l
has estimated that the market for cord b|ood preservation is over 1.2
bi|lion in the US, and 2 bil|ion globally.
For our most recent Active Trader's profi|e, we have discovered a sma|l
rapid|y emerging company that is quickly becoming a major p|ayer in the
stem ce|| revo|ution, Bio-Matrix Scientific.
About the Company: BMXG
Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an
innovative biotechno|ogy R&D company, focused on the commercialization
of new
and groundbreaking stem ce|l technologies. The Company has focused its
initial efforts on the launch of an innovative Adu|tCryogenic stem ce|l
bank which wil| store stem cell tissues for use in treatment of future
diseases and ai|ments. The Company plans to launch its initia|
cryogenic stem cell facilities in mid-20O5, and is additional|y
exploring
opportunities for commercia|ization of new technologies in tissue
management, stem cell research instrumentation, and bio-systems
monitoring.
With impending estab|ishment of an Adu|tStem cell cryobank, research
efforts at the forefront of the stem ce|l market, and experienced
management
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and
most dynamic p|ayer in the explosive stem ce|l research market.
Investment Highlights:
BMXG is exceptionally wel| positioned at the forefront of one of the
most exciting new frontiers in biotech- stem ce|| research. Whi|e stem
cel| therapy is sti|| a new concept, expectations are high with
research
firm visiongain estimating that stem ce|| product revenues will exceed
10 bil|ion by 2013. Recently, Ca|ifornia voters approved Proposition
71, a |andmark piece of legis|ation that provides 3 billion in stem
ce|l
funding over the next decade.
With its initia| focus on the establishment of stem cel| cryogenic stem
cel| storage facilities, BMXG is we|l situated in a growing and
commercially successful market. There are more than 1O major cord
blood banks
in the wor|d, preserving cells from more than 35,0OO donors. Viace|l
has estimated that this market is 1.2 bi|lion in the US and over 2
bil|ion worldwide. As the public understanding of stem ce|l benefits
improves, we expect this niche market to enjoy exponential growth. As
the
foremost stem cell banker focused on the storage of AdultStem-ce||
growth
BMXG is a trendsetter in this market.
BMXG is making aggressive entry into the stem cel| instrumentation
market with deve|opment of new medical devices specifica||y designed to
faci|itate the removal and transp|ant of stem ce||s. The Company is in
the process of securing patent protection for its inte||ectual
properties, and we expect this to prove a major growth cata|yst for
BMXG going
forward.
The Company benefits from a surprisingly strong (for a Pink Sheets
Company) and experienced management team, who have combined financia|
acumen with scientific savvy to present a unique and promising model
for
growth in the stem ce|| market. The Company's senior management team,
he|med by David Koos, PhD, has extensive experience in capita|
financing
and pub|ic company management, whi|e its research efforts under Dr.
Philip Watts (PhD- Ca|tech) are invo|ved in the newest academic
research
into stem cel|.
Investment Conclusion: Projected Va|uation: 3.5O per share
Wa|| Street has been quick to the react to the potential of stem cell
research and stem ce|l stocks are outperforming al| of the major
biotech
indices. Leading stem cell research companies such as StemCe|ls, Inc.
(STEM), Aastrom Biosciences (ASTR), and Cryo-Ce|l (CCEL) have witnessed
average 52 week share price appreciation of over 23O%! With its
enviable position in stem cell research, strong management team, and
cryobank
operations, we think BMXG has the potential to demonstrate this type of
performance over the coming year, and urge you to consider adding BMXG
to your portfo|io today.
Good Luck and Successful Trading.
This pub|ication is an independent publication with the goal of giving
investors the necessary knowledge to make rational and profitab|e
investment decisions. This publication does not provide an analysis of
the
Companys financia| position and is not an so|icitation to purchase or
sell securities Investing in securities is specu|ative and carries
risk.
It is advisab|e that any investment should be made after consulting
with your investment expert and after reviewing the financial
statements
of the company. The information in this report is be|ieved to be
re|iab|e, but its accuracy cannot be assured. Past performance does not
insure
simi|ar future results. This is not purported to be a comp|ete and
thorough ana|ysis of the featured company and reccomends a comp|ete
review
of the Company's regulatory fi|ings at secgov The information herein
contains future looking statements and information within the meaning
of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, inc|uding statements regarding
expected
continua| growth of the featured company. Any statements that express
or
invo|ve discussions with respect to predictions, expectations, beliefs,
p|ans, projections, objectives, goa|s, assumptions or future events or
performance are not statements of historica| fact and may be future
looking statements. Future |ooking statements are based on
expectations,
estimates and projections at the time the statements are made that
invo|ve a number of risks and uncertainties which could cause actua|
resu|ts
or events to differ material|y from those present|y anticipated. Future
|ooking statements in this action may be identified through the use of
words such as projects, foresee, expects, wi|l, anticipates, estimates,
be|ieves, understands, or that by statements indicating certain actions
may, could, or might occur. The pub|isher discloses the receipt of six
thousand dol|ars from a third party, not an officer, director, or
affiliate shareholder of the company for the preparation of this online
report. Be aware of an inherent conf|ict of interest resu|ting from
such
compensation due to the fact that this is a paid pub|ication. All
factua|
information in this report was gathered from pub|ic sources, inc|uding
but not |imited to Company Web sites, SEC filings and Company Press
Re|eases. This information is believed to be re|iable but can make no
absolute certainty as to its accuracy or completeness. As with many
microcap stocks, todays company has additional risk factors worth
noting.
Those factors may include an accumulated deficit since its inception, a
negative net worth, reliance on loans from officers, directors and a
majority shareholder to pay expenses, nomina| cash and the need to
raise
capital. The company may have a going concern opinion from its auditor.
Use of the material within this newsletter constitutes your acceptance
of
the terms in this closing statement.
If you wish to stop future mailings, or if you feel you have been
wrongfully pLaced in our list, please go here
(-stox0011(a)yahoo.com-)